Exploring the Association Between Schizophrenia and Cardiovascular Diseases: Insights into the Role of Sigma 1 Receptor

Overview

Journal Physiol Res

Specialty Physiology

Date 2023 Aug 11

PMID 37565416

Authors

J Rafcikova

M Novakova

T Stracina

Affiliations

Soon will be listed here.

Abstract

Contemporary society is characterized by rapid changes. Various epidemiological, political and economic crises represent a burden to mental health of nowadays population, which may at least partially explain the increasing incidence of mental disorders, including schizophrenia. Schizophrenia is associated with premature mortality by at least 13-15 years. The leading cause of premature mortality in schizophrenia patients is high incidence of cardiovascular diseases. The specific-cause mortality risk for cardiovascular diseases in schizophrenia patients is more than twice higher as compared to the general population. Several factors are discussed as the factor of cardiovascular diseases development. Intensive efforts to identify possible link between schizophrenia and cardiovascular diseases are made. It seems that sigma 1 receptor may represent such link. By modulation of the activity of several neurotransmitter systems, including dopamine, glutamate, and GABA, sigma 1 receptor might play a role in pathophysiology of schizophrenia. Moreover, significant roles of sigma 1 receptor in cardiovascular system have been repeatedly reported. The detailed role of sigma 1 receptor in both schizophrenia and cardiovascular disorders development however remains unclear. The article presents an overview of current knowledge about the association between schizophrenia and cardiovascular diseases and proposes possible explanations with special emphasis on the role of the sigma 1 receptor.

Citing Articles

Exploring the Frontier of Cyclic Dipeptides: A Bioinformatics Approach to Potential Therapeutic Applications in Schizophrenia.

Li X, Nong X, Yang J, Li M, Wang Q, Sun M Int J Mol Sci. 2024; 25(21).

PMID: 39518975 PMC: 11546255. DOI: 10.3390/ijms252111421.

References

Attar R, Valentin J, Freeman P, Andell P, Aagaard J, Jensen S . The effect of schizophrenia on major adverse cardiac events, length of hospital stay, and prevalence of somatic comorbidities following acute coronary syndrome. Eur Heart J Qual Care Clin Outcomes. 2018; 5(2):121-126. DOI: 10.1093/ehjqcco/qcy055. View

Fleetwood K, Wild S, Smith D, Mercer S, Licence K, Sudlow C . Severe mental illness and mortality and coronary revascularisation following a myocardial infarction: a retrospective cohort study. BMC Med. 2021; 19(1):67. PMC: 7983231. DOI: 10.1186/s12916-021-01937-2. View

Sambo D, Lebowitz J, Khoshbouei H . The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction. Pharmacol Ther. 2018; 186:152-167. PMC: 5962385. DOI: 10.1016/j.pharmthera.2018.01.009. View

Mailman R, Murthy V . Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr Pharm Des. 2009; 16(5):488-501. PMC: 2958217. DOI: 10.2174/138161210790361461. View

Nasrallah H, Meyer J, Goff D, McEvoy J, Davis S, Stroup T . Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006; 86(1-3):15-22. DOI: 10.1016/j.schres.2006.06.026. View

Smith S . Introduction to Sigma Receptors: Their Role in Disease and as Therapeutic Targets. Adv Exp Med Biol. 2017; 964:1-4. DOI: 10.1007/978-3-319-50174-1_1. View

Novakova M, Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y . Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur J Pharmacol. 1995; 286(1):19-30. DOI: 10.1016/0014-2999(95)00424-j. View

Roberts L, Roalfe A, Wilson S, Lester H . Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract. 2006; 24(1):34-40. DOI: 10.1093/fampra/cml054. View

Chen Y, Pan C, Chang C, Chen P, Chang H, Tai M . Physical Illnesses Before Diagnosed as Schizophrenia: A Nationwide Case-Control Study. Schizophr Bull. 2020; 46(4):785-794. PMC: 7342094. DOI: 10.1093/schbul/sbaa009. View

10.

Nichols D . N,N-dimethyltryptamine and the pineal gland: Separating fact from myth. J Psychopharmacol. 2017; 32(1):30-36. DOI: 10.1177/0269881117736919. View

11.

Nuwayhid S, Werling L . Sigma1 receptor agonist-mediated regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C. J Pharmacol Exp Ther. 2002; 304(1):364-9. DOI: 10.1124/jpet.102.043398. View

12.

Bora E, Binnur Akdede B, Alptekin K . Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med. 2017; 47(14):2401-2413. DOI: 10.1017/S0033291717000952. View

13.

Yung N, Wong C, Chan J, Chen E, Chang W . Excess Mortality and Life-Years Lost in People With Schizophrenia and Other Non-affective Psychoses: An 11-Year Population-Based Cohort Study. Schizophr Bull. 2020; 47(2):474-484. PMC: 7965070. DOI: 10.1093/schbul/sbaa137. View

14.

Ayerbe L, Forgnone I, Addo J, Siguero A, Gelati S, Ayis S . Hypertension risk and clinical care in patients with bipolar disorder or schizophrenia; a systematic review and meta-analysis. J Affect Disord. 2017; 225:665-670. DOI: 10.1016/j.jad.2017.09.002. View

15.

Baker R, Mahmud A, Miller I, Rajeev M, Rasambainarivo F, Rice B . Infectious disease in an era of global change. Nat Rev Microbiol. 2021; 20(4):193-205. PMC: 8513385. DOI: 10.1038/s41579-021-00639-z. View

16.

Salaciak K, Pytka K . Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders. Neurosci Biobehav Rev. 2021; 132:1114-1136. PMC: 8559442. DOI: 10.1016/j.neubiorev.2021.10.037. View

17.

Lurie I, Shoval G, Hoshen M, Balicer R, Weiser M, Weizman A . The association of medical resource utilization with physical morbidity and premature mortality among patients with schizophrenia: An historical prospective population cohort study. Schizophr Res. 2021; 237:62-68. DOI: 10.1016/j.schres.2021.08.019. View

18.

Quadir S, Cottone P, Sabino V . Role of Sigma Receptors in Alcohol Addiction. Front Pharmacol. 2019; 10:687. PMC: 6586921. DOI: 10.3389/fphar.2019.00687. View

19.

Peritogiannis V, Ninou A, Samakouri M . Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management. Healthcare (Basel). 2022; 10(12). PMC: 9777663. DOI: 10.3390/healthcare10122366. View

20.

Crawford K, Bowen W . Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002; 62(1):313-22. View